BioSpace News Archive

Business

China’s CanSinoBIO Partners with Canada’s Precision NanoSystems on COVID-19 Vaccine

PNI will handle development of the vaccine and CanSinoBIO will take care of preclinical testing, human clinical trials, regulatory submissions and commercialization.

May 21, 2020
·
3 min read
·
Mark Terry
Business

BioSpace Movers & Shakers, May 22

Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

May 21, 2020
·
4 min read
·
Alex Keown
Policy

U.S. Government Provides AstraZeneca More Than $1 Billion for COVID-19 Vaccine

The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.

May 21, 2020
·
7 min read
·
Mark Terry
Business

Sorrento Responds to Criticism of COVID-19 Neutralizing Antibodies

Henry Li, Sorrento’s co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.

May 21, 2020
·
11 min read
·
Mark Terry
Drug Development

ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials

To learn more about ImmunityBio’s HIV drug candidate, BioSpace spoke to Dr. Whitney and Jeffrey Safrit, PhD, director of Cell-Mediated Therapies in Virology at NantKwest.

May 21, 2020
·
9 min read
·
Chelsea Weidman Burke
FluoGuide A/S is Awarded Best IPO in 2019 by the Independent IPO Guide

Affärsvärlden’s IPO Guide announced that FluoGuide A/S won the 2019 share price development award in the micro-cap category and also received the honorary quality award.

May 21, 2020
·
4 min read
Policy

Biopharma Update on the Novel Coronavirus: May 21

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.

May 21, 2020
·
4 min read
·
BioSpace Editorial Staff
Drug Development

High Dose of Gilead and Galapagos’ JAK-Inhibitor Filgotinib Hits the Mark in UC Study

A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.

May 21, 2020
·
2 min read
·
Alex Keown
Business

Caution Urged As Hopes Hinge on COVID-19 Vaccine Development

The hopes of billions of people are riding on at least one of the vaccine candidates for COVID-19 currently in clinical development becoming a commercialized preventative treatment for the world. While hopes are high, caution is still being urged by drugmakers and epidemiologists.

May 21, 2020
·
3 min read
·
Alex Keown
Genetown

Boston’s HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B

Two years after Boston-based HotSpot Therapeutics launched, the company has secured $65 million in Series B funding to advance the development of its allosteric therapies that target “regulatory hotspots” in the body into the clinic.

May 21, 2020
·
3 min read
·
Alex Keown